The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

Brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor, received accelerated approval in the United States for the treatment of patients with metastatic ALK(+) non–small‐cell lung cancer who have progressed on or are intolerant to crizotinib. A clinical study was conducted to asses...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Pharmacol Drug Dev
Huvudupphovsmän: Tugnait, Meera, Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Sonnichsen, Daryl, Kerstein, David, Dorer, David J., Narasimhan, Narayana
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2018
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767012/
https://ncbi.nlm.nih.gov/pubmed/30570839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.641
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk